Open AccessInteractions between Alcohol and the HIV Entry Inhibitor Maraviroc
Author(s) -
Valerie A. Gruber,
Petrie M. Rainey,
Paula J. Lum,
George Beatty,
Francesca Aweeka,
Elinore F. McCanceKatz
Publication year - 2013
Publication title -
journal of the international association of providers of aids care (jiapac)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 31
eISSN - 2325-9582
pISSN - 2325-9574
DOI - 10.1177/2325957413495567
Subject(s) - maraviroc , pharmacokinetics , medicine , alcohol , pharmacology , drug , ccr5 receptor antagonist , placebo , human immunodeficiency virus (hiv) , virology , biology , receptor , biochemistry , chemokine , alternative medicine , pathology , chemokine receptor
Background: Alcohol use is common among people with HIV, and beliefs about alcohol interactions with medications predict decreased medication adherence, risking drug-resistant mutations. Maraviroc is an HIV entry inhibitor approved for treatment of both drug-sensitive and drug-resistant HIV strains. The present study evaluated the effects of alcohol on maraviroc pharmacokinetics and the effects of maraviroc on alcohol pharmacokinetics.Methods: Ten healthy adults completed alcohol (1 g/kg) and placebo alcohol pharmacokinetics sessions before and after 7 days of maraviroc administration.Results: Alcohol concentrations increased 12% following maraviroc. Maraviroc pharmacokinetics were unaffected by alcohol.Conclusions: Maraviroc treatment should not be interrupted if alcohol is consumed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom